LUCIDITY phase 3 topline data presented at CTAD for HMTM - t

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in the field, where the focus has largely been on the role of beta-amyloid. Experts in the field are increasingly looking at alternative therapeutic approaches to find a breakthrough treatment that offers clinically meaningful benefit, ease of administration and low burden of care associated with a reassuring safety profile. Supporting a path to regulatory submissions, the most recent data from LUCIDITY shows sustained improvement in cognition over 18 months over pre-treatment levels in those participants with MCI due to AD, building on previous data shared in October 2022. This treatment effect was seen only at the 16 mg/day dose of HMTM. Sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied. Coupled with the strong safety profile, convenient oral administration, and lack of need for more than routine clinical monitoring, this positions HMTM as a game-changing prospect for the future treatment of this global unmet need. On hearing the data and explanations for the path forward from TauRx, Dr George Grossberg, Professor, Director Division of Geriatric Psychiatry Department of Psychiatry & Behavioural Neuroscience, St Louis University School of Medicine, commented, "It is encouraging to see data on a potential disease modifying therapy focusing on the role of Tau in Alzheimer's disease. Being an oral agent with a good safety profile is another advance in the disease-modifying arena for Alzheimer's disease." TauRx will announce further data on completion of the 24-month study in mid-2023, with additional blood-based biomarker data commissioned to be available early next year. Meanwhile, TauRx is preparing for regulatory submissions primarily in the UK, US, and Canada, with other key territories on their target list, including China, to follow alongside additional studies. The recent announcement of additional investment of USD119 millionthrough a warrants exercise triggered by the study results allows the company to move forward with regulatory submissions and preparation for market availability. ABOUT LUCIDITY LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies. Additional data analysis is ongoing in relation to the 1-year open label phase of the trial, secondary endpoints including MRI volumetric brain scans, and exploratory endpoints. A summary of the LUCIDITY study protocol has recently been published in The Journal of Prevention of Alzheimer's Disease http://dx.doi.org/10.14283/jpad.2022.63). https://www.luciditytrial.com ABOUT TAURx PHARMACEUTICALS LTD The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology. Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases. https://www.taurx.com TAU PATHOLOGY IN ALZHEIMER'S Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer's. These tangles disrupt and damage neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer's, establishing it as an important target for treatment. HMTM is a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.

Related Keywords

China , Canada , United Kingdom , Singapore , San Francisco , California , United States , Scotland , George Grossberg , St Louis University School Of Medicine , University Of Aberdeen , Taurx Pharmaceuticals Ltd , Clinical Trials , Director Division , Geriatric Psychiatry Department , Behavioural Neuroscience , Au Aggregation Inhibitor , Imtm , S An Oral Drug Witha Strong Safety Profile , Aving No Risk Of Amyloid Related Imaging Abnormalities Topline Results For The Phase 3 Study , Lucidity , Ere Shared At The Clinical Trials In Alzheimer 39s Disease Ctad Conference On Wednesday , 0th November 2022 , N San Francisco For People With Early Alzheimer 39s Mci , Mtm Improvement In Cognition Over Pre Treatment Baseline Now Shown To Be Sustained 18 Months Aberdeen , Scotland And Singapore , Dec 1 , 022 Prnewswire Taurx Pharmaceuticals Ltd Isa Global Leader In Tau Based Research Alzheimer 39s Disease Ad , Eing The Only Company Running Late Stage Clinical Trials Fora Potential Therapy Designed To Target Tau Pathology Of Alzheimer 39s Pathological Aggregation Correlates With Disease Severity And Brain Atrophy Asa Hallmark , T Is Recognised Asa Key Target For Disease Modifying Treatments This Approach By Taurx Contrasts To Many In The Field , Here The Focus Has Largely Been On Role Of Beta Amyloid Experts In Field Are Increasingly Looking At Alternative Therapeutic Approaches To Finda Breakthrough Treatment That Offers Clinically Meaningful Benefit , Ase Of Administration And Low Burden Care Associated Witha Reassuring Safety Profile Supportinga Path To Regulatory Submissions , He Most Recent Data From Lucidity Shows Sustained Improvement In Cognition Over 18 Months Pre Treatment Levels Those Participants With Mci Due To Ad , Uilding On Previous Data Shared In October 2022 This Treatment Effect Was Seen Only At The 16 Mg Day Dose Of Hmtm Sustained Cognitive Improvement Over Baseline Has Not Been With Any Other Late Stage For Alzheimer 39s Currently Being Studied Coupled Strong Safety Profile , Onvenient Oral Administration , Nd Lack Of Need For More Than Routine Clinical Monitoring , His Positions Hmtm Asa Game Changing Prospect For The Future Treatment Of This Global Unmet Need On Hearing Data And Explanations Path Forward From Taurx , R George Grossberg , Professor , Irector Division Of Geriatric Psychiatry Department Amp Behavioural Neuroscience , Commented , Uot It Is Encouraging To See Data Ona Potential Disease Modifying Therapy Focusing On The Role Of Tau In Alzheimer 39s Being An Oral Agent Witha Good Safety Profile Another Advance Arena For Quot Taurx Will Announce Further Completion 24 Month Study Mid 2023 , Ith Additional Blood Based Biomarker Data Commissioned To Be Available Early Next Year Meanwhile , Aurx Is Preparing For Regulatory Submissions Primarily In The Uk , Us , Land Canada , Ith Other Key Territories On Their Target List , Including China , O Follow Alongside Additional Studies The Recent Announcement Of Investment Usd119 Millionthrougha Warrants Exercise Triggered By Study Results Allows Company To Move Forward With Regulatory Submissions And Preparation For Market Availability About Lucidity Is Only Late Stage Clinical Trial Specifically Targeting Tau Pathology Alzheimer 39s Aggregation Abnormal Protein One Hallmark Pathologies Data Analysis Ongoing In Relation 1 Year Open Label Phase , Econdary Endpoints Including Mri Volumetric Brain Scans , Nd Exploratory Endpointsa Summary Of The Lucidity Study Protocol Has Recently Been Published In Journal Prevention Alzheimer 39s Disease Http Dx Doi Org 10 14283 Jpad 2022 63 Https Www Luciditytrial Com About Taurx Pharmaceuticals Ltd Group Companies Was Established 2002 Singapore , Ontinuinga Partnership With The University Of Aberdeen , Ith Primary Research Facilities And Operation Based In Aberdeen , K The Company Has Dedicated Past Two Decades To Developing Treatments And Diagnostics For Alzheimer 39s Other Neurodegenerative Diseases Due Protein Aggregation Pathology Dementia Isa Leading Cause Of Death Throughout World One Most Important Public Health Issues Be Addressed Globally Taurx Will Contribute Addressing This Unmet Need With Data From Lucidity Pursuit Regulatory Approvals In Line Its Overall Plans Commercialise Hmtm Pursue Clinical Trials Related Https Www Com Tau Through Research Programs , T Is Understood That Certain Age Related Factors Lead To Misfolding And Aggregation Of Tau Proteins , Nd The Subsequent Formation Of Tau Tangles In Alzheimer 39s These Disrupt And Damage Neuronal Function , A Process That Begins Many Years Before Symptoms Of Dementia Are Seen Tau Pathology Has Been Proven To Correlate With The Clinical Decline Loss Memory And Ability Care For Oneself Commonly In People Alzheimer 39 S , Stablishing It As An Important Target For Treatment Hmtm Isa Tau Aggregation Inhibitor , Hich Effectively Crosses The Blood Brain Barrier To Target Source Of This Damaging Process ,